Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biotech Venture Funding Surges

by Lisa M. Jarvis
July 29, 2013 | A version of this story appeared in Volume 91, Issue 30

Venture capital investment in the biotech industry surged in the second quarter of 2013 compared with the first quarter of the year, according to a new report from PricewaterhouseCoopers and the National Venture Capital Association. Although the number of deals rose just 4% to 103, the total amount invested grew 41% to $1.3 billion. Moreover, 33 companies in the life sciences sector, which encompasses biotech and medical devices, scored venture capital funding for the first time, up from 22 companies in the first quarter of 2013. “Life sciences investment is poised for a slow and steady recovery,” notes NVCA President Mark Heesen.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.